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ABSTRACT
We assessed the Pill Questionnaire as a screen for
mild cognitive impairment in nondemented Parkinson’s
disease patients.
The relationship between ability to remember medica-
tions for Parkinson’s disease in the Pill Questionnaire,
mild cognitive impairment, and deficits on neuropsy-
chological tests performed 2–3 weeks later blind to Pill
Questionnaire results was assessed in movement dis-
orders clinic patients.
In 109 subjects, inaccurate medication reporting on the
Pill Questionnaire was associated with lower scores on
the Montreal Cognitive Assessment, Scales for Out-
comes in Parkinson’s Disease–Cognition and with defi-
cits in memory, attention, executive function-inhibitory
control, processing speed, visuospatial function, and
language. Inaccurate medication reporting was also
associated with an adjusted odds ratio of 2.4 (95% CI,
0.91–5.88; P 5 .06) for mild cognitive impairment, with
a specificity of 80% and sensitivity of 41%.
The Pill Questionnaire is neither sensitive nor specific
enough to be used as the sole screening or diagnostic
tool for mild cognitive impairment. However, inaccurate
medication reporting is associated with deficits span-
ning many cognitive domains and should alert a
clinician to a higher likelihood of cognitive impairment.
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Cognitive impairment is common in Parkinson’s dis-
ease (PD). PD–mild cognitive impairment (PD-MCI),
characterized by impaired cognition without signifi-
cant functional impairment, has a cross-sectional prev-
alence of 19%–38%.1 Clinical recognition of PD-MCI
is important, as these patients appear to have an
increased risk of developing dementia (PDD).2 A rapid
screen for PD-MCI that is possible to implement in a
busy clinical practice setting would be useful. The
Montreal Cognitive Assessment (MoCA) is a candi-
date tool for screening for PD-MCI.3,4 However, it is
difficult to allocate 10–15 minutes of every patient en-
counter to conduct the test.
The Pill Questionnaire asks patients to describe
their PD medications, the doses, and their intake
times.5 If there is inaccurate reporting of the treat-
ment regimen, a caregiver is asked to verify whether
the patient can take their medications safely and reli-
ably on their own. Difficulty describing their treat-
ment regimen and problems taking their PD
medications independently, as reported by their care-
giver, have both been associated with dementia in PD
patients.6 We tested the hypothesis that patients with
PD-MCI would also have difficulty with this cogni-
tively demanding task. Given that the review of
patient PD medications is already a routine part of
taking a patient history, the Pill Questionnaire could
be a practical screening tool.
Patients and Methods
Consecutive nondemented PD patients were enrolled
at 6 North American movement disorders centers.
Inclusion criteria were the diagnosis of PD according to
United Kingdom PD Society Brain Bank criteria, age
greater than 60 years, no impairment in function
related to cognition according to the modified Disabil-
ity Assessment for Dementia (DAD), no depressive
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disorder (Geriatric Depression Scale  5), caregiver
available for collateral history, minimum of a grade 8
education, English as a first language, and a minimum
standard score of 80 on the Wechsler Test of Adult
Reading. A clinical evaluation was followed 2–3 weeks
later by neuropsychological testing performed blinded
as to the results of the Pill Questionnaire. The clinical
evaluation included the Pill Questionnaire, the MoCA,
Scales for Outcomes in Parkinson’s Disease–Cognition
(SCOPA-COG), Mini–Mental State Examination
(MMSE), Movement Disorders Society Unified Parkin-
son’s Disease Rating Scale (MDS-UPDRS), and self-
reported ability to take PD medications as prescribed.
The neuropsychological battery included 8 core meas-
ures: memory (CVLT-II–Long Delay Free Recall),7
attention (Digit Span–Longest Span Forward),8 execu-
tive function–working memory (Letter–Number
Sequencing),8 executive function–cognitive flexibility
(Visual Verbal Test–Total Number of Shifts),9 execu-
tive function–inhibitory control (Color–Word Interfer-
ence—Time to Complete Condition 3),10 processing
speed (Color–Word Interference—Time to Complete
Condition 1),10 visuospatial function (Visuospatial–
Judgment of Line Orientation),11 and language (Verbal
Fluency–Category Fluency Condition).10
The diagnosis of MCI was made based on modified
Petersen criteria requiring (1) a cognitive complaint
from the subject or caregiver as assessed by the Neu-
robehavioral Inventory, (2) no functional impairment
related to cognition as assessed by the modified DAD,
and (3) performance at least 1.5 standard deviations
below the reported normative mean on 1 or more of
the a priori designated core neuropsychological tests.12
This differs slightly from the more recently published
criteria of the Movement Disorders Society Task
Force, which require impairment on at least 2 neuro-
psychological tests from 1 or more cognitive domains
to diagnose PD-MCI.13
The physician rated each subject’s ability to report
medication on the Pill Questionnaire according to 1 of
5 categories:
1. The patient is able to spontaneously and clearly
describe the drugs, doses, and timing of the
treatment.
2a. The patient needs some help from the examiner
but is successful without clinically pertinent
errors, and the caregiver verifies that the patient
can take the medications safely and reliably.
2b. The patient needs some help from the examiner,
and the caregiver verifies that the patient cannot
take medications safely and reliably.
2c. The patient needs some help from the examiner,
and the caregiver does not know whether the
patient can take medications safely and reliably.
3. The patient is unable to describe medications
even with help from the examiner.
Three measures were used as proxies for the com-
plexity of a patient’s current PD medication regimen:
number of current PD medications, levodopa-equiva-
lent dose (LED), and number of doses listed by the
patient on the Pill Questionnaire.
We dichotomized Pill Questionnaire medication
responses into accurate medication reporting: rating 1
versus inaccurate medication reporting: ratings 2a, 2b,
2c, and 3. Comparisons between these 2 groups were
made using the Student t test for continuous variables,
the 2-proportion z test for the frequency of impairment
(>1.5 standard deviations below the normative mean)
in core neuropsychological tests, and the chi-square test
for the frequency of MCI. Adjusting for the effect of
education, we assessed the relationship between ability
to report medication on the Pill Questionnaire and PD-
MCI (using logistic regression) or neuropsychological
test z scores (linear regression), including years of edu-
cation as an independent variable.
Results
Of 109 Parkinson’s disease patients, 75 (68.8%)
accurately described the drugs, doses, and timing of
treatment (rating 1), 29 (26.6%) needed help describ-
ing medications but could take medications safely and
reliably (rating 2a), 2 (1.8%) needed help describing
medications and could not take medications safely and
reliably (rating 2b), 1 (0.9%) needed help describing
medications and the caregiver was unsure about their
ability to take medications safely and reliably (rating
2c), and 2 (1.8%) were unable to describe their medi-
cations even with help (rating 3).
Subject characteristics are shown in Table 1. There
were no significant differences in PD medication regimen
complexity between patients with accurate and inaccu-
rate medication reporting on the Pill Questionnaire: total
mean number of doses listed by each patient (accurate
reporting, 5.1 6 2.9; inaccurate reporting, 6.0 6 3.3;
P ¼ .17), number of medications for Parkinson’s disease
(accurate reporting, 1.6 6 0.8; inaccurate reporting, 2.0
6 0.9; P ¼ .07), LED (Table 1) or total number of medi-
cations (accurate reporting, 6.6 6 3.7; inaccurate report-
ing, 6.6 6 4.3; P ¼ .93). A slightly higher proportion of
patients with inaccurate medication reporting on the Pill
Questionnaire indicated problems remembering to take
their medication as prescribed (accurate reporting, 9%;
inaccurate reporting, 16%; P¼ .3).
Inaccurate medication reporting on the Pill Ques-
tionnaire was also associated with lower educational
level, lower MoCA, and SCOPA-COG scores, and
increased severity of Parkinson’s disease (MDS-UPDRS
total), particularly motor symptoms (UPDRS part III)
and motor complications (UPDRS part IV) , in addi-
tion to reduced scores in tests of memory, attention,
executive function–inhibitory control, processing
T H E P I L L Q U E S T I O N N A I R E I N P D - M C I
Movement Disorders, Vol. 27, No. 10, 2012 1309
speed, visuospatial function, and language (Tables 1
and 2). After adjusting for level of education, inaccu-
rate medication reporting on the Pill Questionnaire
was associated with significantly reduced scores in ex-
ecutive function–inhibitory control (P ¼ .002), proc-
essing speed (0.015), and language (0.007). Inaccurate
medication reporting was associated with being classi-
fied as impaired (>1.5 SD below the normative mean)
in memory, attention, executive function–inhibitory
control, and language (Table 2). When individuals
rated as 1 or 2a (able to take medications reliably
without supervision) were compared with those rated
as 2b, 2c, or 3 (unable or with uncertain ability to
take medications reliably without supervision), those
Table 1. Patient characteristics according to the Pill Questionnaire assessment
Total (n ¼ 109)
Accurate medication
reportinga (n ¼ 75)
Inaccurate medication
reportingb (n ¼ 34)
P value accurate versus
inaccurate reporting
Age (y) 71.3 6 5.2 70.9 6 5.0 72.3 6 5.5 .2
Male/Female (number) 74/35 53/22 21/13 —
Education (y) 15.9 6 2.5 16.4 6 2.0 14.9 6 3.1 .003
Disease duration (y) 7.0 6 5.2 6.7 6 4.3 7.5 6 6.9 .5
MDS-UPDRS Part I 6.3 6 3.9 5.9 6 3.7 6.9 6 4.0 .2
MDS-UPDRS Part II 8.6 6 5.7 8.0 6 5.2 9.6 6 6.1 .2
MDS-UPDRS Part III 27.4 6 11.2 25.7 6 11.6 30.6 6 9.1 .03
MDS-UPDRS Part IV 2.3 6 3.8 1.7 6 3.0 3.7 6 5.0 .01
MDS-UPDRS Total 44.5 6 17.1 41.2 6 16.0 50.8 6 16.3 .005
Levodopa-equivalent dose (mg) 577.1 6 418.5 563.1 6 423.8 627.9 6 430.6 .5
MMSE 28.1 6 2.1 28.4 6 1.6 27.7 6 2.6 .1
MoCA 24.9 6 3.1 25.4 6 2.8 24.1 6 3.3 .04
SCOPA-COG 27.0 6 5.5 28.0 6 5.0 24.8 6 5.8 .004
MCI (number)
Yes 59 35 24 OR 2.74
No 50 40 10 P ¼ .0236
Values are means with standard deviations unless otherwise indicated. Values in boldface indicate statistically significant differences between groups.
aRating 1.
bRatings 2a, 2b, 2c, or 3.
MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease Rating Scale; MMSE, Mini–Mental State Examination; MoCA, Montreal Cognitive
Assessment; SCOPA-COG, Scales for Outcomes in Parkinson’s Disease–Cognition.
Table 2. Frequency of impairment* in each cognitive domain and corresponding neuropsychological test by Pill
Questionnaire performance
Z scores
Number of patients scoring below 1.5
























Memory (CVLT-II— Long Delay Free Recall)7 0.19 6 0.96 0.32 6 1.57 .04 5 (6.7%) 12 (35.3%) .0001
Attention (Digit Span—Longest Span Forward)8 0.65 6 0.83 0.23 6 1.03 .03 0 (0%) 2 (5.8%) .04
Executive function—working memory
(Letter-Number Sequencing)8
0.48 6 0.81 0.15 6 1.02 .07 2 (2.7%) 2 (5.9%) .4
Executive function—cognitive flexibility
(Visual Verbal Test—Total Number of Shifts)9




0.33 6 0.92 0.33 6 1.37 .004 3 (4%) 5 (14.7%) .05
Processing speed (Color–Word Interference—
Time to Complete Condition 1)10
0.07 6 0.89 0.33 6 1.08 .04 4 (5.3%) 4 (11.8%) .2
Visuospatial (Visuospatial—Judgment
of Line Orientation)11
0.28 6 1.57 0.88 6 1.16 .05 13 (17.3%) 11 (32.4%) .1
Language (Verbal Fluency—Category
Fluency Condition)10
0.45 6 1.24 0.51 6 1.22 .003 4 (5.3%) 6 (17.7%) .04
Values in boldface show statistically significant differences between groups.
*Impairment on a neuropsychological tests is defined as standardized score  1.5 SD below mean from normative scores.
aRating 1.
bRatings 2a, 2b, 2c, or 3.
MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease Rating Scale.
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scoring 2b, 2c, or 3 had significantly lower scores on
core tests of memory, executive function–cognitive
flexibility, and language and on the SCOPA-Cog (Sup-
plementary Table 2).
Fifty-nine of 109 patients met our criteria for PD-
MCI (54%). Inaccurate medication reporting on the
Pill Questionnaire was associated with an odds ratio
of 2.74 for PD-MCI (95% CI, 1.15–6.52; Table 1).
The sensitivity and specificity of the Pill Questionnaire
for detecting PD-MCI were 41% and 80%, respec-
tively (positive predictive value, 71%; negative predic-
tive value, 53%). After adjusting for years of
education and total MDS-UPDRS scores, impaired
medication reporting on the Pill Questionnaire was
associated with an odds ratio of 2.4 for PD-MCI
(95% CI, 0.91–5.88; P ¼ .06). Inability to take medi-
cations reliably without supervision (2b, 2c, or 3) was
associated with an odds ratio of 10.19 for PD-MCI af-
ter zero-cell correction (95% CI, 0.55–189.05; P ¼
.06). Combining inaccurate medication reporting on
the Pill Questionnaire with a MoCA score  26
improved the positive predictive value for detecting
PD-MCI (to 92%) without further compromising sen-
sitivity. In the same data set, the positive predictive
value for PD-MCI of a MoCA score  26 alone was
67%. Following an inaccurate report on the Pill Ques-
tionnaire with the MMSE or SCOPA-Cog was not as
helpful (Supplementary Table 1).
Discussion
Our analysis demonstrated that inaccurate medica-
tion reporting elicited by the Pill Questionnaire is asso-
ciated with cognitive deficits, even in nondemented
individuals. Patients with inaccurate medication report-
ing had lower scores on neuropsychological tests of
memory, attention, and executive function—inhibitory
control, processing speed, visuospatial function, and
language and on cognitive screening tests (MoCA and
SCOPA-Cog). There was no difference in performance
on the MMSE, consistent with previous observations
that the MoCA and SCOPA-Cog are more sensitive to
the early cognitive changes in PD than the MMSE.4
In the current study PD-MCI was associated with inac-
curate medication reporting on the Pill Questionnaire (rat-
ings 2a, 2b, 2c, and 3). However, the Pill Questionnaire is
insufficiently sensitive to be used as the sole screening tool
and not specific enough to be used as a sole diagnostic
test. Interestingly, inaccurate medication reporting on the
Pill Questionnaire in conjunction with a MoCA score less
than or equal to 26 was highly specific for PD-MCI, but
this combination still had poor sensitivity.
As in any study of mild cognitive impairment, the
results will vary depending on the criteria used. For
example, some investigators require more than 1 cog-
nitive test within a domain to be abnormal.13–15 With
more stringent criteria, the sensitivity of the Pill Ques-
tionnaire may be different. Our cohort was highly
educated, and the Pill Questionnaire may perform dif-
ferently in a less educated population of PD patients.
Although the deliberate use of the Pill Questionnaire
to identify individuals with cognitive impairment is
not recommended because of low sensitivity, neurolo-
gists routinely ask their patients about their PD medi-
cations early in the patient encounter, and it is
common for patients to attempt to recall medications
from memory without the aid of a list. Difficulty
reporting a medication regimen should raise the suspi-
cion of cognitive deficits because of the association
with MCI and impairments in a number of cognitive
domains.
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